Pure Global
NCT06418763

The Effects of Fermented Brown Seaweed Intake on Glucose Metabolism and Gut Health

The Effects of Fermented Brown Seaweed Intake on Glucose Metabolism and Gut Health: a Short-term Study in Healthy Subjects
Aventure AB·ClinicalTrials.gov·dietary supplementRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Healthy Subjects
Drug/Device/Intervention
Baobab spread mixed with fermented brown seaweed
Study type
Interventional
Intervention type
dietary supplement
Sponsor & location
Primary sponsor
Aventure AB
Location
Lund, Sweden
Timeline & enrollment
Phase
N/A
Start date
Apr 22, 2024
End date
Jun 30, 2025
Enrollment
25 participants
Primary outcome

Postprandial blood glucose

Summary

The aim of this randomised, controlled, cross-over study is to investigate whether the intake
 of fermented brown seaweed can lower postprandial blood glucose levels and influence the
 composition of the gut microbiota in 25 healthy volunteers. Well-being and gastrointestinal
 symptoms as well as sensory properties of the products will also be evaluated using
 questionnaires.
 
 At the screening visit, the subjects will be informed about the study procedures and
 inclusion/exclusion criteria will be checked. Informed consent will be signed by each subject
 before participating in the study. The participants will consume the active and control
 product, respectively, for 5 days with a 14-day wash-out period in between. Capillary blood
 samples will be drawn for glucose measurement at the first day of each 5-day intervention
 period. Faecal samples will be collected before and after each 5-day intervention period to
 analyse changes in gut microbial composition.

ICD-10 classifications
Occupational health examinationSeeking and accepting physical, nutritional and chemical interventions known to be hazardous and harmfulRoutine child health examinationExamination and observation for other reasons
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06418763
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06418763 through Pure Global AI's free database. This phase not specified trial is sponsored by Aventure AB and is currently Recruiting. The study focuses on Healthy Subjects. Target enrollment is 25 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.